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Abstract 
Rhes (Ras homolog enriched in striatum) has been identified as a novel monomeric G-
protein involved in dopaminergic and other signaling in the striatum.  Given the many 
effects of opioids that involve striatal circuitry, genetically engineered mice that are 
incapable of making Rhes (rhes-/-) and their control littermates (rhes+/+) were subjected 
to behavioral tests to determine if any differences existed in opioid analgesia, tolerance, 
withdrawal, reward, and locomotion.  Rhes-/- mice showed an increased opioid mediated 
analgesia, along with an absence of tolerance and decrease in withdrawal when 
compared with rhes+/+ littermates.  However, no significant changes were seen in opioid 
induced locomotor activation or conditioned place preference.  These results provide 
strong evidence for the implication of Rhes in opioid signaling.   
 
 
 
 
 
 
 
 
 
 
Rhes, analgesia, opioid, tolerance, dependence, GTP-binding protein
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Introduction 
Exogenous opioids are currently the best treatment for severe intractable pain.  
These substances show profound analgesic effect, but at the cost of being highly 
addictive.  Clinicians are tasked with weighing the benefits of these potent analgesics 
against the costs of side effects such as respiratory depression, euphoria, and 
addiction.  Opioid addiction is a major public health concern, especially considering the 
high likelihood of overdose due to its effects on respiration.  Better understanding of the 
mechanisms that lead to both analgesia and addiction can be beneficial in the 
development of therapies that maximize the analgesic effects of opioids while 
simultaneously decreasing the liability of side effects.   
  Given the concerns of using opioids in the treatment of pain, it is important to 
understand the mechanism by which opioids exert their actions in the body.  When 
properly understood in the context of pain and addiction, the mechanisms will help 
scientists to develop therapies that increase the therapeutic window of opioid analgesics 
thereby increasing analgesia and reducing abuse potential.  The mechanisms by which 
opioids exert their actions, despite the large amount of research dedicated to the field, 
are still not well understood.  Basic scientific research continually adds to an 
increasingly complex picture of the action of opioids at both the cellular and systems 
levels.  In the current study, we have attempted to classify the effects of a novel protein 
Rhes (Ras Homolog Enriched in Striatum) in regard to opioid analgesia.  The approach 
focuses on the study of behavior to draw inferences regarding both cellular mechanisms 
in context of the current literature.     
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Rhes, a monomeric G-protein, is known to function as a special type of G-protein 
that does not signal in the same manner as the traditional heterotrimeric G-proteins.  
Rather, Rhes is part of the Ras superfamily of small GTPases that seem to function as 
modulators of traditional G-protein functions (Campbell, Khosravi-Far, Rossman, Clark, 
& Der, 1998; Falk et al., 1999).  Current research suggests that Rhes interferes with the 
intracellular messaging of G protein-coupled receptors (GPCRs), specifically dopamine, 
β-adrenergic, muscarinic, and thyroid-hormone receptors. Our aim was to determine if 
this interference could lead to behavioral changes in opioid induced analgesia, 
tolerance, withdrawal, reward, and locomotion, all of which involve GPCRs in the 
striatum, a place where Rhes has been shown to be localized (Errico et al., 2008; Falk 
et al., 1999; Harrison & LaHoste, 2006). 
G Protein-Coupled Receptors 
 GPCRs, also known as metabotropic receptors, are found throughout the central 
nervous system (CNS), and provide an important means of transduction of signals from 
neurotransmitters to cellular activity.  Every major neurotransmitter, as well as a host of 
hormones, neuropeptides, and exogenous compounds, activates this class of receptors.  
Stimulation of these receptor types plays a role in every type of cellular function from 
altering membrane potential to transcription of genes.  GPCRs can be implicated in 
many illnesses from cancer to schizophrenia.  Understanding the role of GPCR 
signaling is important to understanding the role of such pathologies, and behavior in 
general, at the level of the cell.   
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GPCRs share a homologous structure containing seven membrane spanning 
domains that are connected by extracellular loops that form a ligand binding site 
(Kandel, Schwartz, & Jessell, 2000).  The third intracellular loop is typically attached to 
a heterotrimer, a structure composed of 3 individual proteins.  These G-proteins, alpha 
(α), beta (β), and gamma (γ), are responsible for transmitting extracellular signals via 
GPCRs to intracellular responses of the cell.  When a ligand binds this receptor type, 
the receptor goes through a conformational change that allows the α subunit of the 
heterotrimeric G-protein complex to become activated, uncoupling from a constitutively 
bound guanosine diphosphate (GDP) molecule which is then replaced by a guanosine 
triphosphate (GTP) molecule.  This activates the α subunit and allows it to move away 
from the βγ complex and the receptor. The subunit then moves along the inner 
membrane surface to effector proteins which it can then activate setting in motion any 
number of possible outcomes via activation and inactivation of various intracellular 
signaling pathways.  When this happens, the βγ proteins, which are thought to exist 
mostly in a dimerized state, are allowed to move away from the receptor and can 
activate second messenger cascades as well (Hamm, 1998; Kandel et al., 2000).  
Dopamine Receptors  
Dopamine signaling has been widely studied, and it has been shown that 
dopamine acts through two metabotropic receptor types including the D1 (D1, D5) 
family receptors which operate via coupling to the stimulatory Gs α subunit, and the D2 
(D2,D3,D4) family receptors that couple to the inhibitory Gi/o α subunits.  Both D1 and 
D2 family receptors have been shown to be expressed abundantly in the striatum, 
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nucleus accumbens (NAc), and limbic structures (Missale, Nash, Robinson, Jaber, & 
Caron, 1998).  
Gαs α subunits are so named because of their stimulatory effect on adenylyl 
cyclase (AC).  These subunits, when activated by an agonist bound receptor, have been 
shown to upregulate cyclic adenosine monophosphate (cAMP) through stimulation of 
AC (Kebabian & Calne, 1979; Missale et al., 1998).  Gαi/o are so named because, in the 
presence of an agonist bound receptor, they inhibit the production of cAMP via effects 
on AC (Kandel et al., 2000).  Both excitatory Gαs and inhibitory Gαi/o  coupled  receptors 
are bound  to Gβγα heterotrimers in their resting state (Kandel et al., 2000).  At rest the 
Gα subunit is bound to the Gβγ complex due to its constitutive binding of a GDP 
molecule.  When an agonist is presented, GDP is replaced by GTP which causes a 
conformational change in Gα that disassociates it from the βγ complex, allowing it to 
move along the plasma membrane to a nearby effector protein, AC (Missale et al., 
1998).  Gα subunits have an intrinsic ability to dephosphorylate GTP into GDP, thus 
allowing the subunit to re-associate with the βγ again forming the heterotrimer that is 
associated with the receptor (Missale et al., 1998).   
AC’s major function is the production of cAMP.  cAMP is a soluble intracellular 
second messenger that binds several effector proteins and activates their various 
functions.  Most isoforms of AC are activated by the Gαs/olf, and inactivated by Gαi/o, but 
some forms can also be stimulated by protein kinase C, Ca2+/Calmodulin, and βγ 
signaling (Neve, Seamans, & Trantham-Davidson, 2004).   The main target of cAMP is 
the protein kinase A (PKA).  PKA has been implicated in many cell functions, including 
Ca2+ concentration via regulation of extracellular calcium influx/efflux and intracellular 
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calcium stores, regulation of ion channels, protein inactivation through activation of 
phosphodiesterases and phosphatases, activation of the phopholipase C (PLC) 
pathway, cell proliferation, and gene transcription.  Many regulatory effects of dopamine 
receptors are also a consequence of the signaling of Gβγ, which has been shown to 
regulate AC, and directly interact with the PLC/DAG pathway (Missale et al., 1998; 
Neve et al., 2004).    
Rhes 
Rhes is an intermediate size GTP binding protein that is heavily expressed in the 
striatum of rodents and has a high degree of nucleotide conservation with the Ras 
superfamily of small GTPase proteins (Errico et al., 2008; Falk et al., 1999; Harrison & 
LaHoste, 2006).  Ras GTPases act as cellular switching mechanisms that interact with 
other effector proteins to change specific cellular messaging systems within the 
intracellular cytoplasmic domain (Campbell et al., 1998).  They have been studied 
extensively for their role in the activation of the mitogen-activated protein 
kinase/extracellular signal-rated kinase (MAPK/ERK) signaling pathway which is 
intimately involved in cell proliferation and implicated in the mechanics of many cancers 
(Bos, 1989; Campbell et al., 1998; Rodriquez-Viciana, Sabatier, & McCormick, 2004).  
However, despite the large body of research conducted on the relationship between the 
MAPK/ERK signaling pathways and small GTPases Rhes has not been shown to affect 
MAPK/ERK signaling (Vargiu et al., 2004)(Laura Harrison Unpublished Results).   
Rhes was originally characterized by Falk and colleagues after the discovery of 
its closely related family member Dexras1/AGS1 (1999).  In bacterial cells expressing 
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Rhes, these researchers determined that Rhes did bind GTP, likely giving it intrinsic 
GTPase activity, and that it was induced by thyroid hormone unlike its close relative 
Dexras1, which is induced by dexamethasone (Falk et al., 1999; Kemppainen & 
Behrend, 1998).  This group also made the observation that like Dexras1, Rhes also 
contained an unusually long c-terminus, the part of the protein that is known to 
associate with other proteins, making it likely that these proteins posses unique but 
similar signaling characteristics (Falk et al., 1999).   
Vargiu and colleagues further characterized Rhes (2004).  In situ hybridization 
was performed, and it was determined that the Rhes mRNA was heavily expressed in 
the striatum, but to a lesser extent in the nucleus accumbens, olfactory bulb, olfactory 
tubercle, piriform cortex, hippocampus, anterior thalamic nuclei, inferior colliculus, 
cerebellum, cortex, and outside of the CNS in the thyroid.  A later study provided 
evidence that expression of Rhes is determined by dopamine innervation.  By 
experimentally lesioning dopaminergic projections, a decrease in rhes mRNA was 
measured in the caudate putamen and shell of NAc suggesting that rhes expression is 
regulated by dopaminergic tone and also that supersentivity of dopamine receptors 
correlates with rhes mRNA downregulation (Harrison & LaHoste, 2006).    
By attaching a GFP (green fluorescent protein) to the CAAX terminal, an area of 
proteins susceptible to membrane binding, researchers were able to determine that 
Rhes is targeted to the plasma membrane in vitro. Through a series of pharmacological 
interventions it was also determined that farnesylation is the most likely candidate for its 
post translational targeting to the membrane (Vargiu et al., 2004).  
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 In vitro immuno-precipitation showed evidence that Rhes did not stimulate the 
MAPK/ERK pathway, but that it did stimulate the phosphoinositide 3-kinase (PI3K) 
pathway (Vargiu et al., 2004).  In vitro GTP binding showed that 30% of Rhes is 
constitutively bound by GTP, meaning its effects remain active at basal conditions.  
Evidence also suggests an inability of several well known guanidine exchange factors 
(GEFs), small proteins that assist in exchanging GTP and GDP molecules on other 
proteins, to alter GTP binding.  Most importantly, Rhes was found to inhibit reporter 
gene activation, a cAMP dependent mechanism, in cells expressing the metabotropic, 
Gαs coupled, thyroid hormone receptor, suggesting that Rhes interferes with signaling of 
Gαs coupled receptors (Vargiu et al., 2004).   This was supported by Errico et al (2008), 
who found that PKA dependent phosphorylation of the GluR1 subunit of the AMPA 
receptor in medium spiny neurons, a direct result of Gαs/olf stimulation of AC/cAMP, was 
increased in rhes-/- membrane preparations (2008).  Since this phosphorylation is a 
direct result of Gαs/olf stimulation of AC/cAMP, it suggests that Rhes provides negative 
modulation of the Gαs/olf stimulation of AC.   
To determine if Rhes modifies Gαi/o signaling like its closest relative Dexras1, 
researchers using PC12 cells transfected with Rhes and the M2-muscarinic receptor 
found no change in reporter gene activity suggesting no alteration of Gαi/o  (Vargiu et al., 
2004).  Errico et al. (2008) suggested that Rhes may have an effect on Gαi/o signaling 
after finding that in rhes-/- membrane preparations of striatal medium spiny neurons, lack 
of Rhes slightly lowered the ability of D2 agonists to stimulate GTP binding (2008).  A 
later study found that Rhes does influence signaling through Gαi/o.  Cells stably 
expressing the M2-muscarinic receptor were shown to produce maximal inhibition of 
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Cav2.2 channels under agonist stimulation when transfected with mutant Rhes; however 
agonist stimulation produced less inhibition in the presence of fully functioning Rhes, 
suggesting that Rhes attenuated Gαi/o inhibitory signaling (Thapliyal, Bannister, 
Christopher, & Brett, 2008).   
Another important finding of the previously mentioned study was the possible role 
of Rhes’ effect on Gβγ signaling.   This group transfected M2-muscarinic receptor 
expressing cells with Rhes and showed tonic inhibition of Cav2.2 channels, a Gβγ 
mediated effect, versus cells transfected with a Rhes CAAX mutated control (Thapliyal 
et al., 2008).  In a recent study by Hill, Goddard, Ladds, and Davey (2009), cells 
expressing both Rhes and either Gβ1, Gβ2, Gβ3, Gβ4, or Gβ5 were compared, and it was 
found that Rhes showed much more binding affinity for Gβ1-3, but not Gβ4,5 .  These 
results suggest that Rhes could possibly interfere with Gαs binding due to its affinity to 
interact with Gβ1-3, the units that preferentially bind Gαs, and not Gβ4,5, units that 
preferentially bind Gαi/o.  Hill et al. suggest that this might be possible due to the fact that 
Gαs interaction with the plasma membrane is much weaker than that of Gαi/o, and 
therefore Gαi/o subunits are able to overcome the interference of Rhes in binding Gβ 
subunits (2009).   
This would lend support to the assertion of Thalapiyal et al. (2008) that Rhes may 
interfere with Gαi/o signaling by allowing the Gαi/o subunit to disassociate from the 
heterotrimeric complex and signal but as this happens allowing Rhes to bind the Gβγ 
subunits disrupting re-association of the Gαi/o subunit with the Gβγ complex.  They 
suggest that this may be due to the ability of Rhes to function as a guanidine exchange 
factor for Gαi/o (Thapliyal et al., 2008).    
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These findings, although unclear almost to the point of contradiction, suggest that 
Rhes may play a differential role depending on what type of receptor complex it targets 
as a function of cell type, receptor type, and expression of the rhes.     
Analgesia  
The classical centrally mediated analgesia pathway has been shown to originate 
in the periacquaductal gray matter (PAG) where mu-opioid binding inhibits GABAergic 
inhibition of serotonergic projection neurons of the rostral ventromedial medulla (RVM).  
These neurons in turn project to the spinal cord where they act to block the incoming 
pain signals of afferent nociceptors (Kandel et al., 2000).  However, mu-opioid receptor 
(MOR) activation is also well known to disinhibit the mesolimbic dopaminergic 
projections of the ventral tegmental area (Altier & Stewart, 1998).  These dopaminergic 
projections send their axons to the limbic structures and most notably to the NAc which 
has been implicated as the reward center of the brain (Kandel et al., 2000).  Through 
activation of the NAc, the mu opioid agonists show great reward and motivation to seek 
these substances.  However the NAc has also been shown to make connections to the 
PAG suggesting that there is a direct modulation of the classical analgesic pathway 
(Ikemoto & Panksepp, 1999).   
A small body of research however has focused on the idea that structures in the 
striatum can themselves be shown to affect analgesia, in particular the NAc.  A study by 
Magnussen and Martin (2002) has shown that direct injection of bupivacaine, an 
anesthetic, into the core of the NAc causes enhanced formalin-induced nociception 
while no effects were shown when the anesthetic was injected into the shell .   Another 
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study found that injection of quinpirole, a potent D2 agonist, into the NAc showed direct 
inhibition of nociception in phase II of the formalin test, and this effect was reversible 
using raclopride, a D2 antagonist (Taylor, Joshi, & Uppal, 2003).  Another 
pharmacological study finds similar effects using D1 agonist and antagonist co-
administered with DAMGO.  A potent MOR agonist DAMGO was co-administered with 
haloperidol, a D2 antagonist, or apomorphine, a D1/D2 agonist.  Results show that 
when administered with haloperidol, DAMGO caused a dose-dependent decrease in 
antinociception in the tail flick assay, and conversely, when administered with 
apomorphine, it showed a dose-dependent increase in antinociception (Capasso, 2008).  
Another study finds that noxious capsaicin administration significantly increases 
mechanical antinociception, but that this effect can be blocked by intra-accumbens 
injection of flupixentol, a non-specific dopamine antagonist (Gear, Aley, & Levine, 
1999).  In light of these studies, dopamine signaling in the striatum becomes an 
important target of centrally mediated analgesic effect.   
Because Rhes is highly expressed in the shell of the NAc, and to a lesser extent 
in the core, and has been shown to affect dopaminergic signaling in the striatum, its 
involvement in signaling may be of importance to NAc mediated analgesia (Errico et al., 
2008; Harrison & LaHoste, 2006; Quintero, Spano, LaHoste, & Harrison, 2008).  Lack of 
rhes in the NAc could cause analgesia by allowing un-modulated activation of the Gαs 
/cAMP pathway in response to stimulation by dopamine projections from the VTA and 
inability for Gαi/o to inhibit this response.  Specifically we hypothesize that rhes-/- mice 
will have increased centrally mediated analgesia.   
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Reward  
The NAc is most notably involved in the rewarding aspects of stimuli and is often 
referred to as the pleasure center of the brain.   The NAc, being part of the basal 
ganglia, is primarily composed of GABAergic medium spiny neurons.   The NAc 
receives input from the VTA, and forms efferent connections with the thalamus, 
striatum, cortex, PAG, and a number of other structures (Ikemoto & Panksepp, 1999).  
The NAc also forms a feedback loop with the VTA, allowing further upregulation of 
dopaminergic tone when salience has been identified thus contributing to instrumental 
conditioning (Hagelberg et al., 2004).   Numerous studies have shown that drugs of 
abuse are linked with dopaminergic upregulation in the NAc, especially in the shell (Di 
Chiara et al., 2004; Marinelli, Rudick, Hu, & White, 2006).  One study shows that both 
D1 and D2 receptor stimulation in the NAc is required to elicit self administration 
(Nakjima, Xinhe, & Lau Loong, 1993).  
Rhes could play a vital role in regulating the ability of dopaminergic inputs to 
affect novel stimulation and continued assignment of salience to exogenous cues.  
Rhes’ ability to modulate both D1 and D2 receptor signaling allows a certain amount of 
error signal to the system.  In mice lacking the Rhes protein, signaling for D1 receptors 
should increase and D2 should decrease.  It is not clear how this will affect reward, as 
the circuitry within the NAc is not clearly defined.  If in fact activation of both receptor 
subtypes is crucial to reward learning, then lack of Rhes may cause an attenuation of 
learning due to overactivation of D1 receptors and underactivation of D2 receptors.   
 12 
 
In the current study we sought to determine if Rhes has effects on either the 
analgesic pathways of the periaqueductal gray and if there is a possible effect on 
mesolimbic dopaminergic pathways involved in analgesia, reward, and locomotion.  The 
Rhes protein has been shown both through behavioral and molecular studies to 
modulate the effects of GPCRs.  Rhes has been shown to differentially effect Gs and 
Gi/o dopamine signaling as well, and we investigated the behavioral effects of this 
signaling on the mesolimbic reward and analgesia pathways.   
Locomotion 
Rhes is expressed in the medium spiny neurons (MSNs) of the striatum (Harrison 
& LaHoste, 2006; Spano et al., 2004).  MSNs of the striatum are inhibitory GABAergic 
cells of two types, those expressing D1 receptors, Substance P, and dynorphins, and 
those expressing D2 receptors and enkephalins.  The cells expressing D1 receptors 
make up the direct circuit of the striatal behavioral activation system, and the cells 
expressing D2 receptors compose the indirect pathways of the striatal behavioral 
activation system.  In the absence of dopamine, the direct and indirect pathways act to 
suppress behavior, but when presented with stimuli that are salient, dopaminergic 
projections from the substantia nigra activate the pathways allowing the direct and 
indirect pathways to disinhibit the thalamus, thus allowing behavioral responses to 
proceed (Kandel et al., 2000).  However, one review suggests that circuitry in the 
striatum is not so straightforward, as there are medium spiny cells that coexpress D1 
family and D2 family receptors, as well as cholinergic interneurons expressing D1/D2 
receptors (Nicola, Surmeier, & Malenka, 2000).  
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In vivo studies have shown that Rhes is normally modulatory of the effects of the 
activation of the striatal system.  In rhes-/- mice, Spano et. al. (2004) showed a slight 
decrease in locomotor activation.  In the same study it was also shown that rhes-/- mice 
showed marked motor coordination deficits as measured by falling in the rotarod test 
(Spano et al., 2004).  One study found that Rhes normally provides negative modulation 
of behaviors that are specific to D1/D2 costimulation and D2 stimulation whereas certain 
D1 behaviors are facilitated (Quintero et al., 2008).  Errico and colleagues, using 
pharmacological ligands specific to D1 and D2 receptors, show that D1 receptor-
mediated behaviors are increased in rhes-/-. They also showed an increase in D2-
antagonist mediated cataleptic response (Spano et al., 2004).  These studies all show 
support for the involvement of Rhes in motor circuitry. However, it is not clear as to 
exactly how Rhes works at the receptor level to modulate behavior.  In the current 
study, we intend to measure locomotor activity in the context of MOR stimulation of the 
ventral tegmental area, as this behavior has been well characterized.  Specifically we 
hypothesize rhes-/- mice will show increased locomotion, replicating previous studies.  
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Design and Methods 
Genotyping 
 All procedures carried out in this study were done under the approval and 
supervision of the University of New Orleans Institutional Animal Care and Use 
Committee (Approval #08-001 & #08-002).  
  All mice used in this study have been bred locally from a colony generously 
donated to Dr. Gerald LaHoste by Dr. Daniela Spano.  Mice were created of a CD1 and 
then backcrossed 10 generations onto a C57BL/6 background. Using a site specific 
homologous recombination, a null mutation was created at the Rhes locus resulting in a 
strain of mice null for the Rhes gene.  An EGFP cassette was inserted into the locus of 
the Rhes gene allowing access to a reporter gene for genotyping.  To determine the 
genotype of the mice, tail biopsies were performed to provide a DNA sample of each 
animal.  DNA was amplified using two separate polymerase chain reactions (PCR), one 
using primers for the wild type allele and one using primers for the EGFP allele which 
only recognizes the null mutation.  Products were separated and imaged using gel 
electrophoresis.  Only male mice between 2-5 months of age were used for behavioral 
testing. 
Tail Biopsy 
  Tail biopsies were performed on mice to render a sample of DNA for genotyping.  
Mice were anesthetized using 100-150 mg/kg of a ketamine/xylazine solution.  Depth of 
anesthesia was checked using toe pinch and corneal reflex.  Once the animal displayed 
no reflex, the distal 2-5 mm of its tail was clipped using a straight razor, and the site was 
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cauterized using a razor blade heated over a spirit lamp.  The tail clipping was placed in 
a solution containing 300μl of DirectPCR™ lysis reagents and 11.6μl of proteinase K.  
Samples were placed on rotation in an incubator at 55˚c overnight to allow for complete 
cell lysis.  Animals were monitored until they had fully recovered from anesthesia.    
Polymerase Chain Reaction 
 After tail samples had incubated at 55˚C overnight, they were placed in an oven 
at 85˚c for approximately 1 hour to deactivate the proteinase K, an enzyme that can 
inactivate the PCR reaction enzymes.  Reactions were prepared consisting 12.5μl 
GoTaq Green Master Mix™ (400 µM dNTPs, 3mM MgCl2, Taq Polymerase, & 
proprietary buffer), 3μl of sense and antisense primers, 11.5μl of nuclease free water, 
and 0.5μl of DNA sample.  Primers for the wild type gene include upstream 5’-
TCCTAGCTCAGCGAGAGGAA-3’, and downstream 5’-
CTAGACAGGGCCCACAGAGA-3’.  Primers for the EGFP reporter include 5’-
CCTACGGCGTGCAGTGCTTCAGC-3’, and 5’-GCGAGCTGCACGCTGCGTCCTC-3’.  
Wild type reactions were allowed to anneal at 60˚C for 30 seconds with a 1 minute 
extension time, whereas EGFP reactions were allowed to anneal at 55˚C for 30 
seconds with a 1 minute extension time.  Both reactions were allowed to complete 35 
cycles and then held at 4˚C to stop the reaction.   
Gel Electrophoresis 
 Gel electrophoresis was carried out using a 3% agarose gel to allow proper 
separation of PCR products.  5μl of each PCR reaction sample was placed in each well.  
A 100bp ladder was used at the distal wells of the gel providing a standard to judge the 
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length of the alleles.  Samples were run through the gel for 5 minutes at 35v to allow the 
DNA to move into the gel evenly.  After the initial 5 minutes the voltage was increased 
to 95v, and the DNA was allowed to run until the marker dyes approached the edge of 
the gel.  The gel was post-stained using a 0.5μg/ml solution of ethidium bromide.  The 
gel was then imaged using a Biorad™ gel imager.  Expected size of the wild type gene 
was 400bp, while expected size of the EGFP reporter was 345bp.   
Supraspinal Analgesia  
To assess the role of Rhes in centrally mediated analgesia we used the formalin 
test paradigm in mice (Tjolsen, Berge, Hunskaar, Rosland, & Hole, 1993).  In the 
formalin test, subjects are injected with a 5% formalin solution in the plantar surface of 
the hindpaw.  Pain was quantified as the amount of time the animals spend licking the 
site of injury.  Formalin initially causes painful injury to the tissue at the site of injection 
leading to immediate nociception due to activation of c-fibers (Tjolsen et al., 1993).  
However, five minutes post injection the original injury is no longer painful as displayed 
by lack of licking and flinching behavior in the animals due to the fixative ability of the 
formalin.  The animals will then begin to lick approximately ten minutes post injection 
leading to the second phase of the formalin test.  In this phase, centrally mediated input 
in the dorsal horn has been sensitized due to the initial c-fiber activation, and now 
allows random firing of the nociceptive pathway despite lack of painful injury (Tjolsen et 
al., 1993).  This second phase of the formalin test is thus a model of chronic 
inflammatory pain that is the result of the failure of efferent pathways to modulate the 
activation of c-fibers in the dorsal horn (Tjolsen et al., 1993).   
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To measure the effects of Rhes on centrally mediated analgesia, separate 
groups of rhes+/+ and rhes-/- mice were tested in the formalin test after receiving i.p. 
injections of 0.0, 3.0 or 10.0 mg/kg morphine. Thirty minutes after drug administration, 
animals received a 40µl s.c. injection of 5% formalin into the plantar surface of one hind 
paw and were placed in an elevated 6”x 6” Plexiglas enclosure with a glass floor. A 
mirror positioned at 45⁰ under the floor allows for un-obscured observation of the 
animal’s behavior. Time spent licking the injected hindpaw was recorded at five minute 
intervals for one hour.   
Spinal Analgesia  
To assess the role of Rhes in spinally mediated analgesia we used the tail flick 
test (Lewis, Sherman, & Liebeskind, 1981; Paronis & Holtzman, 1992).  In the tail flick 
test, a halogen heat source is directed at the distal tip of the tail, and the amount of time 
to withdraw the tail from the source is recorded.  In this test the withdrawal of the tail is a 
reflex mediated by local interneurons in the spinal cord.  As c-fibers are activated, they 
cause activation of a local interneuron that synapses on a motor fiber.  In this way, as 
the nociceptors are turned on, so is the reflex to withdraw.  This reflex requires no input 
from the CNS (although it can be modified by descending input), and therefore allows a 
test of efficacy of analgesics in spinally mediated nociception by their ability to block 
nociceptors from activating the withdrawal reflex.  We hypothesize that presence or 
absence of Rhes will have a minimal affect on this reflexive nocifencisive response due 
to its localization.  The presence of Rhes has not been tested in the spinal cord and at 
present we have no a priori evidence of it being expressed there, therefore it should 
show minimal involvement in a spinal reflex.    
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To determine the effects of Rhes on spinally mediated analgesia, separate 
groups of rhes+/+ and rhes-/- mice were tested in the tail flick test after receiving i.p. 
injections of 0.0, 1.0, 3.0, or 10.0 mg/kg morphine. For tail flick testing, animals were 
held loosely in a towel, and latency to withdraw from a 1 cm2 beam of concentrated 
halogen light shone on the distal 1/3 of their tail was recorded.  Latency to withdraw was 
recorded prior to injection, at 5 minutes post-injection, 15 minutes post injection, and at 
15 minute intervals thereafter for 90 minutes. 
Tolerance 
 Tolerance is an overall term applied to a set of mechanisms that are responsible 
for the decreased ability of a drug to produce an effect.  In the case of exogenous 
opioids, much research is dedicated to determining what these mechanisms are.  
Current research trends lean toward the idea that continued activation of MORs leads to 
a conformational change in those receptors making them desensitized to the exogenous 
opioid, and consequently upregulating the cAMP system.  Compensatory mechanisms 
attempt to correct this system and lead to development of tolerance.  Given that Rhes 
has been shown to couple to several types of GPCR, it is possible that it may play a role 
in MOR signaling.  This part of the experiment was an exploratory analysis of Rhes’ 
effects on opioid tolerance.     
 To test the development of tolerance, rhes+/+ and rhes-/- mice were given 
repeated daily doses of morphine sulfate at a dosage of 3mg/kg.  Before this dosing 
regimen was started, mice were baseline tested for tail withdrawal latency using the tail 
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flick test as described above.  Mice were tested again after the fifth day of repeated 
morphine injections, and latency to withdraw was recorded.   
Withdrawal 
 Opiate withdrawal has been well characterized in the literature, and is a function 
of the supersentivity of the compensatory mechanism of tolerance as explained above.  
To test withdrawal we used a naloxone precipitated withdrawal test.  Rhes+/+ and rhes-/- 
mice were administered repeated injections of morphine over a period of five days at a 
dose of 3mg/kg.  Morphine was allowed to reach peak efficacy by allowing 30 minutes 
to pass.  Animals were then injected I.P. with a 3mg/kg dose of naloxone, a competitive 
mu opioid antagonist.  Animals were then placed in a 6 inch diameter tube that is 1 foot 
tall.  Number of jumps in which the animal’s 4 paws cleared the floor were counted.  
Also, “wet dog shakes” in which the animals entire body shakes much like that of a wet 
dog were counted.  After testing was complete number of fecal boli left in the chamber 
were counted as well.  These scores were combined into a global withdrawal score by 
assigning a weight of 1 to jumps, 5 to wet dog shakes, and 5 to fecal boli, and summed 
for each animal (Christie, 2008).   
Conditioned Place Preference   
To assess the role of Rhes in reward we used the conditioned place preference 
paradigm (Carr, Fibiger, & Phillips, 1989; Tzshentke, 1998).  The conditioned place 
preference (CPP) paradigm is a test designed to assess the rewarding properties of a 
stimulus based on the animal’s preference for cues paired with that rewarding stimulus.  
Rewarding stimuli such as drugs of abuse cause activation of the NAc, the pleasure 
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center of the brain.  The NAc receives input from the cortex, amygdala, and VTA 
(Kandel et al., 2000).  When a stimulus is rewarding, the animal is conditioned to seek 
the context which the stimuli have been previously paired, thus showing a place 
preference.  The animals in this study were placed in two equally salient contexts, one 
paired with morphine and the other with saline, and the ability of the drugs to establish a 
preference for a side were measured by the amount of time spent in each side.  This 
allowed us to determine if Rhes affects place preference, and reward.   
To assess the effects of Rhes deletion on the rewarding properties of morphine, 
separate groups of rhes+/+ and rhes-/- mice were tested in the CPP paradigm. To do this, 
a 6” x 12” Plexiglas chamber was constructed so that the walls and flooring were 
interchangeable.  During habituation and testing trials, the boxes were in a divided 
configuration, split equally into 6” x 6” areas, one with white walls and a wood-chip floor 
and another with black walls and a wire mesh floor.  On drug-pairing trials, the box was 
in a whole configuration, where the entire 6”x12” chamber was arranged to have either 
white walls/wood chip floor or black walls/wire mesh floor. A camera positioned above 
the clear Plexiglas roof of the chamber recorded all behavior during habituation, the first 
morphine trial and the test trial. 
On day one, animals were placed in the divided chamber for a 10-minute 
habituation trial to detect any inherent preference for one side or the other.  The design 
was unbiased, and equal number of animals showed a preference for each side during 
habituation (data not shown).  For the next 3 days, with the boxes in the whole 
configuration, i.p. injections of saline (morning) or 10 mg/kg morphine (afternoon) were 
paired with the environments that were preferred and not preferred during habituation, 
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respectively. Injections preceded placement in the CPP box by 30 minutes to allow the 
drug to take effect, and animals were left in the box for 30 minutes to allow for the 
formation of associations between the drug effects and environmental cues. On the final 
day, drug-free animals were placed in the divided box, and time spent on each side was 
recorded.  Difference scores were calculated such that time spent in the conditioned 
side was subtracted from the time spent in that side on day 1.   
Locomotion 
 To detect the relationship between Rhes and the locomotor effects of morphine, 
video recordings of the animals’ response to a 3mg/kg acute dose of morphine were 
analyzed using AnyMaze ® software.  Mice were placed into a 6” x 12” box and video 
recorded for 10 minutes at 30 minutes post morphine administration.  Distance traveled 
was recorded for 5 minutes beginning after the animal had been in the chamber for 2 
minutes to allow for habituation and compared for the rhes+/+ and rhes-/- mice. 
Statistical Analysis 
For the formalin test of supraspinal analgesia, results are presented as time 
spent licking group means ± SEM for each dose by time.  For statistical analysis, data 
were divided into early (1st 5 minutes) and late (remaining 55 minutes) phases, and 2-
factor (genotype x phase) repeated measures ANOVAs were performed for each dose.    
Tail flick results are presented as a time course for each genotype, which was analyzed 
by 3-factor (dose x time x genotype) repeated measures ANOVA.  These data are also 
presented as latency to withdraw group mean ± SEM for each dose by genotype at the 
30 minute time point.  Tolerance is presented as tail flick latency %MPE [(Tested 
 22 
 
Latency-Baseline Latency)/(Cutoff Latency-Baseline Latency) X 100] group mean ± 
SEM for acute and repeated administration of morphine sulfate.  These data were 
analyzed by a two factor (genotype x phase) repeated measures ANOVA.  Results of 
withdrawal are presented as global withdrawal score group mean ± SEM.  Global 
withdrawal score means were compared by genotype using independent samples t-test.  
Results of the CPP test are presented as group mean of difference score ± SEM.  
These results were analyzed using independent samples t-test.  Locomotion data are 
presented as group mean ± SEM.  The data were analyzed using independent samples 
t-test.  Follow up planned comparisons were made as necessary, and multiple 
comparisons were subject to a modified Bonferroni correction beginning with an α of p < 
0.05.    
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Results 
 
Supraspinal Analgesia 
In the formalin test, rhes-/- and rhes+/+ mice did not show any differences in licking 
in the early or late phase when administered vehicle [F(1,18)=0.424, p > 0.05] or 
morphine at a dose of 3 mg/kg [F(1,17)=0.155, p >0.05] (Figure 1a and b).  However, 
when administered a dose of 10 mg/kg of morphine, rhes-/- mice showed significantly 
less licking in the late phase [F(1,18)=6.587, p <.05] compared with rhes+/+ mice (figure 
1c).  This finding suggests that at higher doses of morphine, rhes-/- mice show increased 
supraspinal analgesia.  Figue 1d shows the time course of formalin induced licking for 
each genotype by dose.   
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Figure 1.  No differences in supraspinally mediated analgesia were observed 
between rhes-/- and rhes+/+ mice when administered (A) 0mg/kg or (B) 3 mg/kg 
morphine.  However, at (C) 10mg/kg of morphine, rhes-/- displayed significantly less 
licking than rhes+/+ mice.  (D) Time course of formalin nociception displayed as time 
spent licking at 5 minute intervals beginning with injection of formalin.   
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Spinal Analgesia 
Results for the tail flick test yielded an expected interaction effect for time x dose 
[F(27)=5.195, p < 0.001], as well as an interaction effect of time x genotype [F(9)=2.516, 
p <0.01] (figure 2a and b).  Follow up comparisons of time points by genotype indicate 
that rhes-/- mice showed a significant shift in time to onset of analgesia such that the 
maximum efficacy was realized at 30 minutes [t(29)=3.303, p <0.01], whereas rhes+/+ 
mice did not reach maximum efficacy until the 45 minute time point [t(29)=2.879, p 
<0.01].   Analgesia was attenuated in rhes+/+ beginning at the 90 minute time point 
[t(29)=-2.532, p <.01], whereas rhes-/- mice remained analgesic [t(29)=-1.557, p >0.05].  
An unexpected main effect of genotype was also present [F(1,52)=6.168, p < 0.05].  A 
planned comparison of the 30 minute time point for each dose reveals that at 1mg/kg 
[t(8)=3.598, p < 0.01] and 3mg/kg [t(17)=3.577, p < 0.01], rhes-/- mice are more sensitive 
to the effects of morphine than rhes+/+ (figure 2 c).  It should be noted that a cutoff of 12 
seconds was imposed in this test to prevent tissue damage.  It is very possible that 
rhes-/- would have shown much more analgesia when administered 10mg/kg of 
morphine, however, at every time point past 15 the rhes-/- mice reached the cutoff, 
whereas the rhes+/+ mice did not achieve a ceiling effect.  Thus rhes-/- mice display 
enhanced spinal analgesia relative to rhes+/+ littermates.    
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Spinal Analgesia 
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Figure 2.  Time course of tail flick test of spinally mediated nociception presented as 
time to withdraw for (A) 0mg/kg and 1mg/kg morphine, as well as (B) 3mg/kg and 
10mg/kg of morphine.  (C) Planned comparison of 30 minute time point for each 
genotype by dose indicating rhes-/- show greater sensitivity to 1mg/kg and 3mg/kg of 
morphine when compared with rhes+/+ mice. 
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Tolerance & Withdrawal 
To test for effects of Rhes on adaptation to repeated morphine treatment, mice 
were given repeated injections (over 5 days) of morphine and tested for tolerance, using 
the tail flick test, to the analgesic effects of 3 mg/kg morphine at 30 minutes post-drug 
administration.  Results of the tolerance test indicate significant main effects for 
genotype [F(1,15)=33.10, p < 0.01] and time [F(1,19)=6.354, p <0.05] (figure 3), and no 
significant interaction [F(9, 153)=1.649, p >0.05].  Rhes+/+ mice showed significantly 
reduced %MPE after both the acute [t(16)=-4.395, p <0.001] and repeated morphine 
administration [t(16)=-6.191, p <0.001] compared with rhes-/- mice.  This result is 
expected given that rhes+/+ show a later onset of morphine induced analgesia compared 
with rhes-/- as presented in the tail flick test.  Rhes+/+ mice also showed significantly 
reduced %MPE between the acute and chronic administrations [t(9)=-2.303, p <0.05], 
whereas rhes-/- showed no significant difference between administrations [t(9)=-.362, p 
>0.05] indicating induction of tolerance in rhes+/+ but not rhes-/- mice (Figure 3a).   Global 
withdrawal scores for rhes-/- mice were significantly decreased [t(19)=-4.241, p<0.001] 
as compared with rhes+/+ mice (figure 4).    
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Figure 3.  Tolerance to the effects of morphine represented as acute (day one) percent 
maximum possible effect versus repeated (day 5) percent maximum possible effect.  
These results indicate that rhes+/+ mice show a significantly decreased maximal 
possible analgesic effect of morphine after repeated administrations, whereas rhes-/- 
showed no difference between acute and chronic administrations.   
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Figure 4.  Withdrawal displayed as global withdrawal scores by genotype.  Results show 
a significantly lower amount of withdrawal behaviors measured in rhes-/- mice when 
compared with rhes+/+ mice.   
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Conditioned Place Preference and Locomotion 
 Rhes-/- mice did not show any difference in conditioned place preference when 
compared to rhes+/+ [t(6)=0.702, p > .05] (figure 5).  Similarly, rhes-/- mice did not show 
any significant difference in locomotor activity when compared to rhes+/+ mice 
[t(7)=0.092, p > 0.05] (figure 6).  It should be noted that the sample size for these 
groups was very low.   
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Figure 5. Place preference displayed as time spent in the conditioned chamber by 
genotype.  Rhes-/- mice did not significantly differ in morphine induced preference when 
compared to rhes+/+ mice. 
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Figure 6.  Rhes-/-  mice did not travel significantly farther than rhes+/+ mice when 
administered 3mg/kg or morphine.   
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Discussion 
 Results of this study indicate that we have supported our hypothesis that rhes-/- 
mice show increased supraspinal analgesia when compared to rhes+/+ littermates.  We 
found evidence to the contrary of our hypothesis that rhes-/- mice would show no 
differences in spinally mediated analgesia when compared with rhes+/+ mice.  Further 
exploratory experiments regarding opioid induced tolerance and withdrawal have shown 
that lack of Rhes does modify opioid tolerance and withdrawal.  We also failed to find 
any differences between rhes-/- mice and rhes+/+ littermates in opioid induced locomotor 
activity or conditioned place preference, however these hypothesis were not adequately 
tested.   
Supraspinal Analgesia 
Rhes-/- mice show an increase in supraspinal analgesia.  However, interpreting 
the effects of Rhes’ action in this centrally mediated response becomes important.  As 
demonstrated (Capasso, 2008), D1/D2 agonists in conjunction with a potent mu opioid 
agonist can cause an increase in spinally mediated analgesia, however, a D2 agonist 
(Taylor et al., 2003) can similarly effect antinociception in the NAc.  As hypothesized, 
lack of Rhes may be able to cause an upregulation of activation of Gαs as a result of 
increased dopaminergic afferent activation from the VTA into the NAc, however this 
hypothesis is inadequately supported by the current literature.  As discussed below, 
analgesia in the striatum is a D2, not a D1 effect.  It cannot be ruled out that lack of 
Rhes’ effect is a result of the attenuation of signaling through Gαi/o, in which case any 
agonist stimulation would result in a net increase of cAMP as a result of inability to 
inhibit AC.  These mechanisms are not mutually exclusive, and it is also equally 
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plausible that lack of Rhes results in the overactivation of Gαs and understimulation of 
Gαi/o.  Antinociception in the nucleus accumbens has been shown to be an effect of 
stimulation of D2 receptors with or without the involvement of D1 receptors (Magnusson 
& FIsher, 2000; Morgan & Franklin, 1991; Taylor et al., 2003).   In our experiments, 
Rhes-/- mice do not show a change in baseline nociception in either the formalin or tail 
flick test, suggesting that Rhes is not contributing to pronociceptive processes.  This 
does not support the hypothesis that lack of Rhes results solely in an upregulation of 
cAMP, be it through increases in AC activation via Gαs or attenuation of signaling 
through Gαi/o.  In fact, given this hypothesis, lack of Rhes should provide for 
pronociception and at least some attenuation of morphine induced analgesia. 
Spinal Analgesia 
 Further complication in interpreting the results of the supra-spinally mediated 
analgesia results from the test of spinally mediated analgesia.  Rhes-/- mice show 
greater sensitivity to morphine induced analgesia as compared with rhes+/+ mice.  No 
prior attempt has been made to asses Rhes expression in the spinal cord.  In this study 
we were operating under the assumption that any involvement of Rhes in Supraspinal 
analgesia would be the result of descending modulation to the spinal cord. Indeed, 
morphine has been shown to cause a supraspinal activation of neurons responsible for 
inhibiting the tail flick reflex (Hanaoka et al., 1978; Sinclair, Main, & Lo, 1988), but this is 
complicated by the fact that much of morphine’s effect can be attributed to local action 
at the site of the dorsal horn neurons (Soja & Sinclair, 1983).   In the current study 
animals were injected with morphine systemically, suggesting that at least much of the 
anti-nociception in the tail flick reflex is a result of morphine acting at µ-opiate receptors 
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in the dorsal horn.  However, involvement of central dopaminergic systems in the 
control of the tail-flick reflex has been demonstrated (Capasso, 2008; Hnasko, Sotak, & 
Palmiter, 2005; King, Bradshaw, Chang, Pintar, & Pasternak, 2001; Kiritsy-Roy et al., 
1994).  The methodologies employed in these studies do little to pinpoint the exact 
locus of dopamine’s control on antinociception at the spinal level. Dopamine’s actions 
on spinal antinociception have been seen not only in the striatum but in the PAG 
(Meyer, Morgan, Kozell, & Ingram, 2009), and through projections to the spinal cord 
itself (Levant & McCarson, 2001; Millan, 2002).  A western blot provided by Dr. Laura 
Harrison reveals no detection of Rhes in the spinal cord; however this may be an 
aberration of the antibody, which may not be sensitive enough to detect low levels of 
protein.  Preliminary RT-PCR does suggest that rhes mRNA is present in the spinal 
cord.  Future evaluation of the presence or absence of Rhes expression in the spinal 
cord could help to explain these results and guide future work.    
One explanation in this case would be that Rhes, being striatally enriched, exerts 
its antinociceptive effects via dopamine receptors in the striatum. This is an incomplete 
explanation given previous findings regarding the involvement of Rhes in dopamine 
signaling.  Future work using site specific delivery of specific agonists and antagonists 
in rhes-/- and rhes+/+ mice would provide much information regarding the contribution of 
Rhes to dopamine signaling in analgesia.  Given the result of both the supraspinal and 
spinal test of analgesia, alternative explanations of Rhes’ effect on analgesia are 
warranted.   
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Tolerance and Withdrawal 
Rhes-/- mice showed no effect of tolerance and very little withdrawal to morphine 
compared to rhes+/+ mice. These results are intriguing.  Tolerance is the phenomenon 
by which increasing doses of a drug are needed to yield the same behavioral effect as a 
function of repeated use of that drug.  The cellular response of repeated administration 
of the drug leads the cell to undergo compensatory mechanisms for prolonged 
exposure.  It is widely accepted that morphine shows a very high affinity and efficacy at 
the MOR although it is considered a partial agonist.  The MOR is a GPCR much like D1 
and D2 family receptors, couples to Gαi/o, and when activated causes the inhibition of 
cAMP (Harrison, Kastin, & Zadina, 1998).  A major effect of the activation of the MOR is 
the activation of the inwardly rectifying potassium channel which acts to shunt excitatory 
transmission, thereby inhibiting the cell (Christie, 2008; Harrison et al., 1998).    
Administration of morphine causes rapid onset of tolerance, leading to the need 
for increasing amounts of drug to evoke this same cellular response.  The mechanisms 
that underlie tolerance are not so clear.  Many studies have shown that tolerance is 
affected by a multitude of cellular and synaptic events.  The overarching effects of these 
events seem to involve the ability of the receptor to couple to its effector 
(desensitization), ability of the receptor to internalize, and the sensitization of AC 
(Christie 2008).  Each one of these mechanisms is reliant upon the activation of the 
GPCR and the subsequent activation of the signaling cascades that regulate them.   
The current literature suggests that the locus of Rhes actions in dopamine 
signaling lies within the pathway between receptor and the first effector (AC).  This 
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mechanism is more or less analogous in opiate receptor signaling.  Given in vitro 
evidence, Rhes has been shown to affect the signaling of other GPCRs besides the D1 
and D2 family receptors.  Rhes is heavily expressed in the striatum in neurons that are 
known to coexpress both dopamine and MORs.  In light of these findings, it is not out of 
the question that Rhes may affect signaling through opiate receptors, and in particular 
the MOR.   Unpublished data from Laura Harrison’s lab provide compelling evidence 
that this may be the case.  Assays of GTP binding in striatal membrane preperations 
using Endomorphin-1, a potent endogenous opioid, have found that Rhes promotes 
binding to Gαi/o.  Given that Rhes has been shown to promote signaling through Gαi/o, 
loss of Rhes should hypothetically cause an inability of MOR to inhibit production of 
cAMP through AC, if Rhes does indeed act at the MOR the same as what has been 
seen in the D2R and M2-muscarinic receptor.  This does not fit very well with what has 
been observed behaviorally in the tests of supraspinal and spinal analgesia.  Lack of 
Rhes in vivo has been shown here to increase morphine induced analgesia, while also 
decreasing tolerance and withdrawal.    
One signaling pathway can explain both of these phenomena.  Rhes has been 
shown to possibly interfere with the binding of GPCR to the heterotrimeric subunits of 
the G-protein motif.  Both Thapliyal et al. (2008) and Hill et. al (2009)  hinted at the idea 
that Rhes may interfere with the association of the α subunits to either the receptor or 
the βγ subunit.  Rhes could promote signaling through βγ, thereby activating the 
phospholipase C - inositol 1,4,5-triphosphate/diaglycerol - protein kinase C pathway 
(PLC-PKC).  PKC has been shown to be important in opioid analgesia, tolerance, and 
withdrawal.  Numerous studies using pharmacological and genetic approaches have 
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shown that blockade of the PKC can cause an attenuation of MOR desensitization and 
tolerance, to some degree based on the agonist (Bailey et al., 2009; Xie et al., 1999).  
This mechanism seems to be uniquely efficacious in the induction of morphine induced 
tolerance whereas tolerance to higher efficacy MOR agonists (i.e. DAMGO) operates 
through a GRK-arrestin mediated mechanism that promotes receptor internalization and 
recycling, a phenomenon that does not happen in agonist stimulation of MORs using 
morphine (Hull et al., 2010).  Studies have also shown that blocking PKC can attenuate 
features of opioid dependence and withdrawal (Cerezo, Laorden, & Milanes, 2002; 
Kogan & Aghajanian, 1995; Maldonado, Valverde, Garbay, & Roques, 1995; Valverde, 
Tzavara, Hanoune, Roques, & Maldonado, 1996). 
Behavioral studies have also indicated that blockade of the activation of the PLC-
PKC pathway results in an increase in antinociception.  One study found that PLCβ3 
knockout mice had a 10 fold increase in morphine induced antinociception (Xie et al., 
1999).  Another study using an agent selected to bind and inactivate signaling through 
βγ subunits found a similar outcome with an increase in morphine induced 
antinociception (Mathews, Smrcka, & Bidlack, 2008).  The phenotype of rhes-/- mice 
closely resembles that of the animals in which βγ signaling, and subsequently PLC-PKC 
activation, was blocked.  Rhes has been shown to increase the GTP binding of Gαi/o 
subunits when presented with a potent MOR agonist.  This would cause an increase in 
the disassociation of the heterotrimeric complex, allowing an increase in the activation 
of βγ subunits.  This in turn could lead to an increase in PKC mediated phosphorylation 
of MOR, and receptor desensitization.   
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Another possibility is that Rhes activates PLC-PKC through Gαq signaling.  Gαq 
has been shown to promote activation of PLC-PKC (Wu, Lee, Rhee, & Simon, 1992).  
Quintero et al. (2008) showed a decrease in grooming in rhes-/- mice, a behavior which 
is mediated by Gαq signaling through D1 receptors.  Promotion of βγ signaling through 
MORs, and promotion of Gαq through D1 colocalized with MORs receptors could both 
contribute to the phenotype seen in this study.   
Conditioned Place Preference and Locomotion 
 No significant differences in locomotion or conditioned place preference were 
found when comparing rhes-/- and rhes+/+ mice.  Previous work has shown that rhes-/- 
mice show an increase in D1 receptor mediated locomotion.  Failure to reproduce this 
result as hypothesized may be due to interactions in signaling between opioid and 
dopamine systems.  Treatment with a D1 agonist in conjunction with morphine 
increases locomotor activation (Funada, Suzuki, & Misawa, 1994).  Deletion of Rhes 
would theoretically provide for an increase in signaling through Gαs causing an increase 
in locomotion, however no differences were found.  One possible explanation is that, in 
the absence of Rhes, modification of MOR signaling in the same cells activates a 
compensatory mechanism that attenuates the effects of upregulation in D1 signaling.    
No modification of place preference was observed in rhes-/- mice.  This result can 
be complicated to interpret given that dopaminergic involvement and MOR signaling can 
affect reward differentially (Petit, Ettenberg, Bloom, & Koob, 1984).  Studies show that 
opioid induced upregulation of cFos and ΔFosB, regulators of gene expression for 
acquiring and maintaining place preference, can be attenuated when given a D1 
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antagonist (Liu, Nickolenko, & Sharp, 1994; Muller & Unterwald, 2005; Nestler & Kelz, 
2000).  Given that deletion of rhes should promote increased signaling through D1 
receptors, deletion of rhes should therefore induce greater place preference.   As with 
locomotion, the unknown variable is the role of Rhes in MOR signaling.  Deletion of 
Rhes may alter the crosstalk between dopaminergic and MOR signaling pathways. 
Interpreting the results of these two investigations is difficult due to 
methodological issues.  Neither experiment had a very large sample, therefore, 
statistically speaking, the results are not robust enough to draw conclusions from.  In 
both tests, only one dose of morphine was administered.  Differences in groups may 
have been overshadowed by either floor or ceiling effects based on dosage.  For 
example, in the test for locomotion, 3mg/kg of morphine is not enough to produce 
morphine hyperlocomotion as seen with 10mg/kg of morphine.  This test would best be 
repeated using a logarithmic dosing scheme to compare groups such that measures 
were taken at 0, 1, 3, and 10mg/kg.  This issue similarly affects the conditioned place 
preference test performed here.  The dose of morphine used, 10mg/kg, is relatively high 
and caused robust place preference in both genotypes.  Subtle differences between 
groups may not have been distinguishable at such a high dose.  The study would also 
best be repeated using logarithmic dosing of morphine.    
Conclusion 
 The results presented in this study provide strong evidence for the involvment of 
Rhes in opioid signaling.  Opiate medications are the most widely used and efficacious 
pharmacological treatment for moderate to severe pain.  Opiate medications, however, 
carry a very high liability including tolerance, withdrawal, abuse, and respiratory 
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depression.  We have shown here a phenotype displayed by mice lacking the Rhes 
protein reduces behaviors associated with opiate drug treatment while increasing the 
efficacy of the desired effect of analgesia.  Clinically, this finding is very important.  
Information regarding Rhes and MOR signaling can lead to the development of 
pharmacological interventions that maximize the efficacy of opiate treatments while 
minimizing the liabilities.   
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